Bioinformatics
Saber Samadiafshar; Ali Nikakhtar; Sahel Samadiafshar; Nadia Garmsiri; Farnia Garmsiri; Roghayeh Azizi; Somayaeh - Farahmand
Volume 1, Issue 1 , March 2025, , Pages 11-16
Abstract
Background: Kidney renal clear cell carcinoma account for 2-3% of the global cancer burden and has the highest death rate of any genitourinary malignancy. Apoptosis is one of the natural immune cycles that fight against cancers. MicroRNAs are small non-coding RNA molecules that can influence the function ...
Read More
Background: Kidney renal clear cell carcinoma account for 2-3% of the global cancer burden and has the highest death rate of any genitourinary malignancy. Apoptosis is one of the natural immune cycles that fight against cancers. MicroRNAs are small non-coding RNA molecules that can influence the function of proteins.Methods: The functional cycles of four microRNAs (133b, 155, 185, 217) involved in kidney cancer apoptosis were identified. Then, the effects of 7 selected medications which is routinely used by specialist doctors to treat cancer (Cabozantinib, Doxorubicin, Everolimus, Nelarabine, Sorafenib, Sunitinib, and Temsirolimus) on the target proteins were evaluated with dynamic techniques and molecular docking. Docking with powerful servers was evaluated in terms of the possibility of occurrence. Finally, the chemical and medicinal properties (Admet), toxicity, mutagenicity, and site of action of the selected drugs were predicted in silico.Results: The results indicated that drug Sunitinib had the best binding energy with 5 target proteins (VHL= -5, VEGF-A= -7.1, BACH1= -7.4, CUL4B= -5.1, JAK-2= -8 (kcal/mol)) and showed acceptable results in terms of molecular weight (398.5 Dalton), site of action (Mitochondria), and mutagenicity (0.5200 (negative)).Conclusion: The identified evidence demonstrates the positive efficacy and effectiveness of sunitinib in various kidney carcinomas. Targeted therapies are steps towards the targeted increase of apoptosis and the control of cell proliferation and migration, which enable the correct treatment of renal clear cell carcinoma and the prescribing of drugs that cause the least secondary damage to patients.
